Surotomycin + Placebo

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Clostridium Difficile Associated Diarrhea (CDAD)

Conditions

Clostridium Difficile Associated Diarrhea (CDAD)

Trial Timeline

Jan 1, 2009 → Mar 1, 2009

NCT ID

NCT02835105

About Surotomycin + Placebo

Surotomycin + Placebo is a phase 1 stage product being developed by Merck for Clostridium Difficile Associated Diarrhea (CDAD). The current trial status is completed. This product is registered under clinical trial identifier NCT02835105. Target conditions include Clostridium Difficile Associated Diarrhea (CDAD).

What happened to similar drugs?

9 of 20 similar drugs in Clostridium Difficile Associated Diarrhea (CDAD) were approved

Approved (9) Terminated (5) Active (11)

✅Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved

✅Fidaxomicin + VancomycinAstellas PharmaApproved

✅Fidaxomicin + VancomycinMerckApproved

✅Vancomycin + FidaxomicinMerckApproved

✅bezlotoxumab + Vancomycin OralMerckApproved

✅Fidaxomicin 200 mg + Placebo + VancomycinMerckApproved

✅BezlotoxumabMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02835118	Phase 1	Completed	Jul 1, 2009	Oct 1, 2009	Clostridium Difficile Associated Diarrhea (CDAD)
NCT02835105	Phase 1	Completed	Jan 1, 2009	Mar 1, 2009	Clostridium Difficile Associated Diarrhea (CDAD)

Competing Products

20 competing products in Clostridium Difficile Associated Diarrhea (CDAD)

See all competitors

Product	Company	Stage	Hype Score
Metronidazole + Metronidazole-DRF1 + Metronidazole-DRF2	Dr. Reddy's Laboratories	Phase 2	32
Fidaxomicin + Vancomycin + Placebo	Astellas Pharma	Approved	35
Fidaxomicin + Treatment for CDI other than fidaxomicin Type	Astellas Pharma	Pre-clinical	26
OPT-80 + vancomycin	Astellas Pharma	Phase 3	40
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsules	Astellas Pharma	Phase 3	40
Fidaxomicin + Vancomycin	Astellas Pharma	Approved	43
Fidaxomicin + Vancomycin	Merck	Approved	43
fidaxomicin + Placebo	Merck	Phase 3	40
Surotomycin + Placebo	Merck	Phase 1	29
CB-183,315 + Placebo + Vancomycin	Merck	Phase 2	35
MK-6072 + MK-3415A + Placebo + SOC	Merck	Phase 3	40
Vancomycin + Fidaxomicin	Merck	Approved	43
Fidaxomicin	Merck	Pre-clinical	18
Bezlotoxumab + Standard CDI treatment	Merck	Pre-clinical	26
MK-3415 + MK-6072 + MK-3415A + Placebo + SOC	Merck	Phase 3	40
Fidaxomicin + Vancomycin + Matching Placebo to Fidaxomicin	Merck	Phase 3	40
bezlotoxumab + Vancomycin Oral	Merck	Approved	43
Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)	Merck	Phase 3	40
Bezlotoxumab Injection [Zinplava]	Merck	Pre-clinical	26
PAR-101/OPT-80 + Vancomycin	Merck	Phase 3	40